Address
Email address
Phone number
Website
http://acino.swiss/ AcinoSwiss based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms.
Name
Acino Estonia OÜ
Registry code
14072902
VAT number
EE101897866
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
30.06.2016 (8)
Financial year
01.01-31.12
Capital
3 000.00 €
Activity
21101 - Manufacture of basic pharmaceutical products
-
-
-
-
-
-
Not submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Arne Randmaa 17.12.1973 (50) | - | Board member | - | |
| Ebe Laanes 14.01.1971 (53) | - | Board member | - | |
| Katrin Madissoo 17.03.1973 (51) | - | Board member | - | |
| Takeda Pharma OÜ 10323690 | - | - | - | Founder |
| 2019 20.04.2020 | 2020 18.05.2021 | 2021 17.06.2022 | 2022 21.06.2023 | |
|---|---|---|---|---|
| Total Revenue | 6 952 000 € | 7 674 000 € | 10 147 000 € | 17 930 000 € |
| Net profit (loss) for the period | 617 000 € | 379 000 € | 838 000 € | 2 004 000 € |
| Profit Margin | 9% | 5% | 8% | 11% |
| Current Assets | 2 175 000 € | 2 637 000 € | 5 750 000 € | 5 517 000 € |
| Fixed Assets | 2 443 000 € | 2 951 000 € | 3 802 000 € | 4 563 000 € |
| Total Assets | 4 618 000 € | 5 588 000 € | 9 552 000 € | 10 080 000 € |
| Current Liabilities | 945 000 € | 1 448 000 € | 4 530 000 € | 3 680 000 € |
| Non Current Liabilities | 600 000 € | 688 000 € | 732 000 € | 106 000 € |
| Total Liabilities | 1 545 000 € | 2 136 000 € | 5 262 000 € | 3 786 000 € |
| Share Capital | - | - | - | - |
| Equity | 3 073 000 € | 3 452 000 € | 4 290 000 € | 6 294 000 € |
| Employees | 64 | 69 | 77 | 93 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 7 346 327.07 € | 418 259 € | 438 521.49 € | 104 |
| 2023 Q4 | 8 124 460.83 € | 446 448.23 € | 469 144.33 € | 106 |
| 2023 Q3 | 5 652 436.24 € | 414 969.19 € | 434 891.57 € | 106 |
| 2023 Q2 | 8 184 640.75 € | 532 092.15 € | 561 775.98 € | 104 |
| 2023 Q1 | 5 704 327.81 € | 387 601.7 € | 406 252.15 € | 104 |
| 2022 Q4 | 6 096 541.56 € | 363 460.99 € | 380 871.13 € | 100 |
| 2022 Q3 | 5 082 856.74 € | 352 660.73 € | 373 409.95 € | 100 |
| 2022 Q2 | 5 528 779.67 € | 508 357.74 € | 540 004.98 € | 93 |
| 2022 Q1 | 5 142 279.46 € | 295 005.91 € | 309 808.98 € | 88 |
| 2021 Q4 | 4 333 205.58 € | 283 208.08 € | 295 439.09 € | 80 |
| 2021 Q3 | 2 205 239.97 € | 279 258.74 € | 295 525 € | 77 |
| 2021 Q2 | 1 902 974.13 € | 404 041.33 € | 431 640.21 € | 73 |
| 2021 Q1 | 1 916 799.23 € | 228 199.59 € | 241 843.33 € | 70 |
| 2020 Q4 | 2 402 984.8 € | 236 494.29 € | 248 089.69 € | 70 |
| 2020 Q3 | 1 744 116.3 € | 230 792.77 € | 245 004.07 € | 68 |
| 2020 Q2 | 2 008 086.65 € | 368 145.17 € | 367 262.81 € | 68 |
| 2020 Q1 | 2 417 087.7 € | 278 704.75 € | 230 818.6 € | 70 |
